As Emergent BioSolutions works rapidly to deal with problems at its Bayview, Md., facility and get production of the Johnson & Johnson (J&J) COVID-19 vaccine back online, the company is reporting some good vaccine news, announcing positive two-year mid-stage trial results for its chikungunya virus vaccine hopeful.